Myopia has gained increasing interest in recent years, particularly because of its increase in prevalence across populations worldwide. The onset of myopia has shifted to a younger age, and the number of high myopes with prescriptions of more than -5.00 D has increased over the last few decades. High myopia is strongly associated with a greater incidence of pathologic complications, has shown to impact vision-related quality of life in children and adults and is further associated with certain contact lens complications. Different pharmaceutical and optical treatment options are currently under investigation with a common goal to slow down the rate of myopia progression.